PMID- 25883891
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 2196-2979 (Print)
IS  - 2196-2979 (Electronic)
VI  - 2015
DP  - 2015 Mar 6
TI  - Neuroimaging Biomarkers for Psychosis.
PG  - 1-10
AB  - BACKGROUND: Biomarkers provide clinicians with a predictable model for the 
      diagnosis, treatment and follow-up of medical ailments. Psychiatry has lagged 
      behind other areas of medicine in the identification of biomarkers for clinical 
      diagnosis and treatment. In this review, we investigated the current state of 
      neuroimaging as it pertains to biomarkers for psychosis. METHODS: We reviewed 
      systematic reviews and meta-analyses of the structural (sMRI), functional (fMRI), 
      diffusion-tensor (DTI), Positron emission tomography (PET) and spectroscopy (MRS) 
      studies of subjects at-risk or those with an established schizophrenic illness. 
      Only articles reporting effect-sizes and confidence intervals were included in an 
      assessment of robustness. RESULTS: Out of the identified meta-analyses and 
      systematic reviews, 21 studies met the inclusion criteria for assessment. There 
      were 13 sMRI, 4 PET, 3 MRS, and 1 DTI studies. The search terms included in the 
      current review encompassed familial high risk (FHR), clinical high risk (CHR), 
      First episode (FES), Chronic (CSZ), schizophrenia spectrum disorders (SSD), and 
      healthy controls (HC). CONCLUSIONS: Currently, few neuroimaging biomarkers can be 
      considered ready for diagnostic use in patients with psychosis. At least in part, 
      this may be related to the challenges inherent in the current symptom-based 
      approach to classifying these disorders. While available studies suggest a 
      possible value of imaging biomarkers for monitoring disease progression, more 
      systematic research is needed. To date, the best value of imaging data in 
      psychoses has been to shed light on questions of disease pathophysiology, 
      especially through the characterization of endophenotypes.
FAU - Hager, Brandon M
AU  - Hager BM
AD  - Massachusetts Mental Health Center Division of Public Psychiatry, Beth Israel 
      Deaconess Medical Center, Department of Psychiatry, Harvard Medical School, 75 
      Fenwood Road, 5th Floor, Boston, MA 02115 USA (617) 754-1244.
FAU - Keshavan, Matcheri S
AU  - Keshavan MS
AD  - Massachusetts Mental Health Center Division of Public Psychiatry, Beth Israel 
      Deaconess Medical Center, Department of Psychiatry, Harvard Medical School, 75 
      Fenwood Road, 5th Floor, Boston, MA 02115 USA (617) 754-1256.
LA  - eng
GR  - R01 MH078113/MH/NIMH NIH HHS/United States
GR  - R01 MH092440/MH/NIMH NIH HHS/United States
GR  - R01 MH096942/MH/NIMH NIH HHS/United States
PT  - Journal Article
PL  - Switzerland
TA  - Curr Behav Neurosci Rep
JT  - Current behavioral neuroscience reports
JID - 101626570
PMC - PMC4394385
MID - NIHMS669768
OTO - NOTNLM
OT  - MRS
OT  - PET
OT  - fMRI
OT  - neuroimaging biomarkers
OT  - psychosissMRI
COIS- Conflict of Interest Brandon Hager and Matcheri Keshavan have no relevant 
      disclosures.
EDAT- 2015/04/18 06:00
MHDA- 2015/04/18 06:01
PMCR- 2016/03/06
CRDT- 2015/04/18 06:00
PHST- 2015/04/18 06:00 [entrez]
PHST- 2015/04/18 06:00 [pubmed]
PHST- 2015/04/18 06:01 [medline]
PHST- 2016/03/06 00:00 [pmc-release]
PST - ppublish
SO  - Curr Behav Neurosci Rep. 2015 Mar 6;2015:1-10.